Eli Lilly, a pharmaceutical giant, invests over $1 billion in India and reports robust third-quarter profit growth expectations, with a 441.5% increase YOY. Analysts foresee a 77.1% profit expansion for the fiscal year. The stock underperforms the market but analysts remain bullish, with a consensus “Strong Buy” rating and a mean price target of $909.88.

Read more at Yahoo Finance.: Here’s What to Expect From Eli Lilly’s Next Earnings Report